BIOMAT Database Logo BIOMAT Database Logo

Recombinant influenza vaccines. 2012

E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
Gamaleya Research Institute of Epidemiology and Microbiology, Gamaleya Str., 18, Moscow, Russia, 123098.

This review covers the problems encountered in the construction and production of new recombinant influenza vaccines. New approaches to the development of influenza vaccines are investigated; they include reverse genetics methods, production of virus-like particles, and DNA- and viral vector-based vaccines. Such approaches as the delivery of foreign genes by DNA- and viral vector-based vaccines can preserve the native structure of antigens. Adenoviral vectors are a promising gene-delivery platform for a variety of genetic vaccines. Adenoviruses can efficiently penetrate the human organism through mucosal epithelium, thus providing long-term antigen persistence and induction of the innate immune response. This review provides an overview of the practicability of the production of new recombinant influenza cross-protective vaccines on the basis of adenoviral vectors expressing hemagglutinin genes of different influenza strains.

UI MeSH Term Description Entries

Related Publications

E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
Soluble recombinant influenza vaccines.
December 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences,
E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
Recombinant vaccines for influenza virus.
August 2008, Current opinion in investigational drugs (London, England : 2000),
E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
Recombinant vectors as influenza vaccines.
January 2009, Current topics in microbiology and immunology,
E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
Recombinant influenza-virus vaccines: II. Some properties of high-yielding recombinant influenza viruses and their vaccines.
June 1976, The Kitasato archives of experimental medicine,
E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance.
January 2019, Frontiers in immunology,
E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.
February 2021, Molecular pharmaceutics,
E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
[Immunogenicity of recombinant influenza virus vaccines (author's transl)].
December 1979, Uirusu,
E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
Recombinant influenza-virus vaccines. III. Isolation and preliminary characterization of so-called antigenic recombinant influenza viruses.
September 1976, The Kitasato archives of experimental medicine,
E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines.
March 1997, Vaccine,
E S Sedova, and D N Shcherbinin, and A I Migunov, and Iu A Smirnov, and D Iu Logunov, and M M Shmarov, and L M Tsybalova, and B S Naroditskiĭ, and O I Kiselev, and A L Gintsburg
New options for influenza vaccines: quadrivalent, recombinant, and cell culture.
January 2013, Journal of the American Pharmacists Association : JAPhA,
Copied contents to your clipboard!